Anatomic Stage III Breast Cancer AJCC v8

Oncology·MeSH: Triple Negative Breast Neoplasms

Prevalence

287.0 / 100K

Incidence

128.0 / 100K/yr

10 drugs in development·4 companies·20 clinical trials

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
JAK Inhibitor	ENANTA PHARMACEUTICALS INC (ENTA)
SGLT-2 inhibitor	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 2(5)

Drug	Company
Perflutren Lipid Microspheres	Lantheus Holdings, Inc. (LNTH)
Perflutren Lipid Microspheres	Merus N.V. (MRUS)
PI3K-beta Inhibitor GSK2636771	ENANTA PHARMACEUTICALS INC (ENTA)
Propranolol	Structure Therapeutics Inc. (GPCR)
Propranolol Hydrochloride	Structure Therapeutics Inc. (GPCR)

Phase 1(2)

Drug	Company
BET Bromodomain Inhibitor ZEN-3694	ENANTA PHARMACEUTICALS INC (ENTA)
Poly Polymerase Inhibitor	ENANTA PHARMACEUTICALS INC (ENTA)

Preclinical(1)

Drug	Company
STAT6 inhibitor program	ENANTA PHARMACEUTICALS INC (ENTA)

BioSniper tracks 10 drugs in development for Anatomic Stage III Breast Cancer AJCC v8 across 4 companies.

There are 20 clinical trials targeting Anatomic Stage III Breast Cancer AJCC v8 tracked by BioSniper.

The estimated prevalence of Anatomic Stage III Breast Cancer AJCC v8 is approximately 287.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.